Amarin (NASDAQ:AMRN) Issues Quarterly Earnings Results

Amarin (NASDAQ:AMRN) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), Zacks reports. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%.

Amarin Trading Down 8.2 %

Amarin stock traded down $0.04 during trading on Wednesday, reaching $0.43. The company had a trading volume of 2,732,678 shares, compared to its average volume of 1,133,226. Amarin has a 52 week low of $0.40 and a 52 week high of $1.11. The firm has a market capitalization of $177.41 million, a price-to-earnings ratio of -4.80 and a beta of 1.82. The firm’s 50-day simple moving average is $0.56 and its 200 day simple moving average is $0.55.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Amarin from a “sell” rating to a “hold” rating in a research note on Friday, March 7th.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.